Default company panoramic image
99c8dfe3 1b5a 4019 a5f4 6f142f5a28b5


ViraTherapeutics develops highly potent cancer-destroying (oncolytic) viruses that are effective in a broad range of different cancers.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Innsbruck, Austria
  • Currency EUR
  • Employees 3

Company Summary

ViraTherapeutics develops anti-cancer agents based on the oncolytic (cancer-destroying) virus VSV-GP. VSV-GP is highly effective in all cancers tested in mouse models. VSV-GP is the only oncolytic virus so far that does not induce neutralizing (virus inactivating) antibodies and therefore can be given repeatedly without loss of efficacy. Thus, VSV-GP-therapeutics have the potential to revolutionize cancer therapy.


  • Default avatar
    Ludwig Weiss

    CEO, co-founder, 50
    -studied biology at the Ludwig-Maximilians-University in Munich
    -PhD degree at the Max-Planck-Institute of Biochemistry
    -Head of gene therapy research group in the Department of Virology
    -18 publications in peer-reviewed journals
    - Management degree, University of Augsburg
    -Certified rating analyst, Standard & Poor’s
    -Study of international patent and trademark law
    -Management of biotech company from founding to e

  • Default avatar
    Meike Dorothee von Laer
    Prof. Dr., MD

    Initiator, co-founder, CSO, 54
    - Inventor VSV-GP technology
    - 1986 Medical degree
    - 1986-2010 Research physician at the universities of Hamburg, Freiburg and Frankfurt
    -2000 Co-founder + part-time CSO of the Vision7 GmbH, Hamburg
    -Head Division for Virology, Innsbruck Medical University
    -Advisory board of the Paul-Ehrlich-Institute, German drug administration
    -Review board Go-BIO funding program of German government

  • Default avatar
    Lisa Egerer

    COO, 32
    -2009 PhD, University Frankfurt
    -2010-12 Postdoc, Division of Virology, Innsbruck Medical University
    -2012- COO ViraTherapeutics
    -Additional training in patent law, project management and quality management
    -6 publications in peer reviewed journals
    - inventor for 1 patent family

Previous Investors

  • Default avatar
    Austrian Wirtschaftsservice Pre-Seed funding
    Default avatar
    CAST Pre-Seed funding